{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:48:30Z","timestamp":1762642110374,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008781","name":"Pomeranian Medical University","doi-asserted-by":"publisher","award":["FSN 343-10\/14"],"award-info":[{"award-number":["FSN 343-10\/14"]}],"id":[{"id":"10.13039\/501100008781","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundation Scio et Preaveceo"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.cmi.2018.06.028","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T04:14:58Z","timestamp":1530764098000},"page":"513.e1-513.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters"],"prefix":"10.1016","volume":"25","author":[{"given":"M.","family":"Parczewski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kordek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Janczewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pisula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"\u0141ojewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141.","family":"Socha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wawrzynowicz-Syczewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Boci\u0105ga-Jasik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Szymczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Cielniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Siwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mularska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Aksak-W\u0105s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Urba\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2018.06.028_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2217\/fmb.09.8","article-title":"HCV genetic variability: from quasispecies evolution to genotype classification","volume":"4","author":"Argentini","year":"2009","journal-title":"Future Microbiol"},{"key":"10.1016\/j.cmi.2018.06.028_bib2","first-page":"29693","article-title":"Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: regulatory analyses and perspectives","volume":"1","author":"Harrington","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2018.06.028_bib3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2018.06.028_bib4","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00535-016-1290-1","article-title":"NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b","volume":"52","author":"Ogawa","year":"2017","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.cmi.2018.06.028_bib5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MEG.0000000000000237","article-title":"Forecasting the disease burden of chronic hepatitis C virus in Poland","volume":"27","author":"Flisiak","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2018.06.028_bib6","first-page":"11","article-title":"Distribution of HCV genotypes in Poland","volume":"67","author":"Panasiuk","year":"2013","journal-title":"Przegl Epidemiol"},{"key":"10.1016\/j.cmi.2018.06.028_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2018.06.028_bib8","first-page":"411","article-title":"Prevalence of hepatitis C virus mutants resistant to protease inhibitors among Polish HCV genotype 1-infected patients","volume":"67","author":"Zabek","year":"2013","journal-title":"Przegl Epidemiol"},{"key":"10.1016\/j.cmi.2018.06.028_bib9","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/QAI.0000000000001628","article-title":"Identifying pre-existing NS3 and NS5A resistance-associated variants and transmission chains in the Polish HIV\/HCV genotype 1 epidemic: impact on prevention and treatment","volume":"77","author":"Parczewski","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2018.06.028_bib10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jcv.2017.04.008","article-title":"A genotype independent, full-genome reverse-transcription protocol for HCV genotyping and resistance testing","volume":"91","author":"Walker","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.cmi.2018.06.028_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1471-2105-14-317","article-title":"Automated analysis of phylogenetic clusters","volume":"14","author":"Ragonnet-Cronin","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.cmi.2018.06.028_bib12","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/hep.27310","article-title":"Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada","volume":"60","author":"Jacka","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2018.06.028_bib13","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"23","author":"Welzel","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.cmi.2018.06.028_bib14","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1128\/AAC.01976-13","article-title":"Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir","volume":"58","author":"Berger","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2018.06.028_bib15","first-page":"696","article-title":"Resistance-associated polymorphisms in Dutch hepatitis C genotype 1a patients with and without HIV infection","volume":"15","author":"Lieveld","year":"2016","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cmi.2018.06.028_bib16","article-title":"Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy","volume":"12","author":"Caudai","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.06.028_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/QAD.0000000000001263","article-title":"The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands","volume":"31","author":"Newsum","year":"2017","journal-title":"Aids"},{"key":"10.1016\/j.cmi.2018.06.028_bib18","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cmi.2015.07.017","article-title":"Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK","volume":"21","author":"Beloukas","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.06.028_bib19","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2018.06.028_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cmi.2018.06.028_bib21","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","article-title":"Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2018.06.028_bib22","first-page":"12850","article-title":"The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naive patients with chronic HCV genotype 1b infection in a real-world cohort","volume":"23","author":"Kozuka","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cmi.2018.06.028_bib23","first-page":"14478","article-title":"Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor","volume":"22","author":"Fourati","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2018.06.028_bib24","doi-asserted-by":"crossref","first-page":"41719","DOI":"10.1038\/srep41719","article-title":"Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment","volume":"7","author":"Eltahla","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2018.06.028_bib25","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/jmv.24255","article-title":"Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy","volume":"87","author":"Yoshimi","year":"2015","journal-title":"J Med Virol"},{"key":"10.1016\/j.cmi.2018.06.028_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2018.06.028_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hep.28255","article-title":"Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3","volume":"63","author":"Peiffer","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2018.06.028_bib28","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.cmi.2018.06.028_bib29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jhep.2015.03.033","article-title":"Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A","volume":"63","author":"Akamatsu","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.cmi.2018.06.028_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.gastro.2010.04.049","article-title":"Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C","volume":"139","author":"Honda","year":"2010","journal-title":"Gastroenterology"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18304932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18304932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:21:48Z","timestamp":1761117708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X18304932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1198743X18304932"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2018.06.028","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2018.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}